Brokerages forecast that Evolent Health Inc (NYSE:EVH) will report ($0.04) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Evolent Health’s earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at $0.01. Evolent Health also reported earnings of ($0.04) per share in the same quarter last year. The business is expected to issue its next earnings report on Tuesday, February 26th.
On average, analysts expect that Evolent Health will report full year earnings of ($0.08) per share for the current fiscal year, with EPS estimates ranging from ($0.17) to $0.00. For the next year, analysts expect that the company will post earnings of $0.22 per share, with EPS estimates ranging from ($0.10) to $0.39. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Evolent Health.
Evolent Health (NYSE:EVH) last posted its earnings results on Tuesday, November 6th. The technology company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. Evolent Health had a negative return on equity of 2.18% and a negative net margin of 9.05%. The business had revenue of $150.16 million during the quarter, compared to analyst estimates of $142.94 million. During the same quarter last year, the firm earned ($0.18) earnings per share. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year.
A number of equities research analysts have weighed in on the company. ValuEngine upgraded Evolent Health from a “hold” rating to a “buy” rating in a research note on Thursday, August 9th. Citigroup raised their price objective on Evolent Health from $25.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, October 4th. Zacks Investment Research lowered Evolent Health from a “hold” rating to a “sell” rating in a research note on Friday, August 10th. Canaccord Genuity raised their price objective on Evolent Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 13th. Finally, Cowen raised their price objective on Evolent Health from $29.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, September 13th. One equities research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the stock. Evolent Health presently has an average rating of “Buy” and a consensus target price of $31.73.
In other Evolent Health news, insider Lydia Stone sold 6,805 shares of the stock in a transaction that occurred on Thursday, August 30th. The stock was sold at an average price of $25.00, for a total transaction of $170,125.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Frank J. Williams sold 3,878 shares of the stock in a transaction that occurred on Monday, August 20th. The stock was sold at an average price of $24.00, for a total value of $93,072.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 204,607 shares of company stock valued at $5,240,751. 4.82% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the business. NumerixS Investment Technologies Inc bought a new position in Evolent Health during the 2nd quarter worth approximately $105,000. DekaBank Deutsche Girozentrale lifted its holdings in Evolent Health by 235.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 6,205 shares of the technology company’s stock worth $156,000 after buying an additional 4,355 shares during the last quarter. LPL Financial LLC bought a new position in Evolent Health during the 1st quarter worth approximately $184,000. Xact Kapitalforvaltning AB bought a new position in Evolent Health during the 1st quarter worth approximately $190,000. Finally, Public Employees Retirement Association of Colorado lifted its holdings in Evolent Health by 106.3% during the 3rd quarter. Public Employees Retirement Association of Colorado now owns 6,904 shares of the technology company’s stock worth $196,000 after buying an additional 3,557 shares during the last quarter.
EVH stock opened at $25.19 on Friday. The company has a quick ratio of 2.59, a current ratio of 2.59 and a debt-to-equity ratio of 0.12. Evolent Health has a 1 year low of $10.30 and a 1 year high of $29.05. The stock has a market capitalization of $1.80 billion, a PE ratio of -35.99 and a beta of 1.50.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
See Also: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.